Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives on the role of TROP2-directed antibody-drug conjugates in the management of HR-positive and triple-negative breast cancers. CME information and select publications here.
-------- Â
20:18
--------
20:18
Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management
Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, discusses the efficacy and safety of approved and investigational antibody-drug conjugates for endocrine-resistant HR-positive and triple-negative metastatic breast cancer. CME information and select publications here.
-------- Â
27:45
--------
27:45
Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies
Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas. CME information and select publications here.
-------- Â
54:07
--------
54:07
For Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS Congress
Drs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clinical perspectives and management strategies from nurse practitioners Ms Jamie Carroll and Mr Ronald Stein. NCPD information and select publications here.
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
South Africa